Plateletcrit levels in patients with psoriasis and its relationship with psoriasis disease severity
Plateletcrit levels in patients with psoriasis and disease severity
Keywords:
Plateletcrit levels, Pustular psoriasis., Psoriasis disease severity, Psoriasis area and severity indexAbstract
Objective The main aim of study was to determine mean plateletcrit level in patients of psoriasis and to compare mean platelecrit level in patients of psoriasis with psoriasis area and severity index < 10 and ≥10. Methods It was a single-center, cross-sectional study carried out at the Department of Dermatology, Pakistan Airforce Hospital, Fazaia Medical College, Islamabad. The study was conducted from 12 October 2020 to 11 April 2021 over a six-month period. Following informed consent, 100 known psoriasis patients were recruited to the study. Proper history was taken, and examination was done to determine disease severity. By computing the Psoriasis Area and Severity Index (PASI), the severity of the disease was evaluated. Plateletcrit level was also determined and was correlated with Psoriasis area and severity index to see if plateletcrit level is increased with score which shows the severity of the disease. Results Mean age of the patients was 44 years. Majority of the patients were males. Mean BMI was 24.7 (kg/m2). Out of 100 patients, 77 (77%) were having psoriasis area and severity index score < 10 while 23 (23%) were having PASI score ≥ 10. Mean value of plateletcrit in patients of psoriasis was 0.284. Mean plateletcrit, in with PASI <10 and PASI ≥10 was 0.261and 0.360 subsequently. Statistics showed that there was a significant difference between the two groups (p˂0.001). Conclusion In conclusion, patients with PASI ≥10, who have psoriasis had higher mean plateletcrit values. In this study, a connection between platetcrit and the severity of psoriasis is established. Given that this is a straightforward test that is part of a full blood analysis. However, thorough interventional trials and translational research are required to better examine the precise clinical significance of plateletcrit in psoriasis.References
Barrea L, Savanelli MC, Di Somma C, Napolitano M, Megna M, Colao A, et al. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Rev Endocr Metab Disord. 2017;18(2):195–205.
Chandrashekar L, Rajappa M, Revathy G, Sundar I, Munisamy M, Ananthanarayanan PH, et al. Is enhanced platelet activation the missing link leading to increased cardiovascular risk in psoriasis? Clin Chim Acta. 2015;446:181–5.
Tamagawa-Mineoka R. Important roles of platelets as immune cells in the skin. J Dermatol Sci. 2015;77(2):93–101.
Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–90.
Zhang S, Yuan J, Yu M, Fan H, Guo Z-Q, Yang R, et al. IL-17A facilitates platelet function through the ERK2 signaling pathway in patients with acute coronary syndrome. PLoS One. 2012;7(7):e40641.
Budak YU, Polat M, Huysal K. The use of platelet indices, plateletcrit, mean platelet volume and platelet distribution width in emergency non-traumatic abdominal surgery: a systematic review. Biochem medica. 2016;26(2):178–93.
Pektaş SD, Alataş ET, Yılmaz N. Plateletcrit is potential biomarker for presence and severity of psoriasis vulgaris. 2016;
Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60(2):218–24.
Katoh N. Platelets as versatile regulators of cutaneous inflammation. J Dermatol Sci. 2009;53(2):89–95.
Akpinar I, Sayin MR, Gursoy YC, Aktop Z, Karabag T, Kucuk E, et al. Plateletcrit and red cell distribution width are independent predictors of the slow coronary flow phenomenon. J Cardiol. 2014;63(2):112–8.
Beyan C. Plateletcrit may not be a useful predictor in patients with slow coronary flow. J Cardiol. 2014;63(3):244.
Fan Z, Wang L, Jiang H, Lin Y, Wang Z. Platelet dysfunction and its role in the pathogenesis of psoriasis. Dermatology. 2021;237(1):56–65.
Aksentijevich M, Lateef SS, Anzenberg P, Dey AK, Mehta NN. Chronic inflammation, cardiometabolic diseases and effects of treatment: psoriasis as a human model. Trends Cardiovasc Med. 2020;30(8):472–8.
Rashid S, Patange RP. Role of platelet indices in non-thrombocytic pih. Int J Health Sci (Qassim). (I):7079–97.
Napolitano M, Mastroeni S, Fania L, Pallotta S, Fusari R, Uras C, et al. Sex‐and gender‐associated clinical and psychosocial characteristics of patients with psoriasis. Clin Exp Dermatol. 2020;45(6):705–11.
Liu Z, Perry LA, Morgan V. The association between platelet indices and presence and severity of psoriasis: a systematic review and meta-analysis. Clin Exp Med. 2022;1–14.
